investigational status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-30. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
For secure communications, the PLA uses the Zhongxing and Fenghuo series of satellites which enable secure data and voice transmission over C-band, Ku-band, and UHF. PLA deployment of anti-satellite and counterspace satellites including those of the Shijian and Shiyan series have also brought significant concern from western nations. The PLA also plays a significant role in the Chinese space program. To date, all the participants have been selected from members of the PLA Air Force. China became the third country in the world to have sent a man into space by its own means with the flight of Yang Liwei aboard the Shenzhou 5 spacecraft on 15 October 2003, the flight of Fei Junlong and Nie Haisheng aboard Shenzhou 6 on 12 October 2005, and Zhai Zhigang, Liu Boming, and Jing Haipeng aboard Shenzhou 7 on 25 September 2008. The PLA started the development of an anti-ballistic and anti-satellite system in the 1960s, code named Project 640, including ground-based lasers and anti-satellite missiles. On 11 January 2007, China conducted a successful test of an anti-satellite missile, with an SC-19 class KKV. The PLA has tested two types of hypersonic space vehicles, the Shenglong Spaceplane and a new one built by Chengdu Aircraft Corporation. Only a few pictures have appeared since it was revealed in late 2007. Earlier, images of the High-enthalpy Shock Waves Laboratory wind tunnel of the CAS Key Laboratory of high-temperature gas dynamics (LHD) were published in the Chinese media. Tests with speeds up to Mach 20 were reached around 2001.
Chymotrypsin is a serine endopeptidase that is present in pancreatic juice and helps the hydrolysis of proteins and peptide. It catalyzes the hydrolysis of peptide bonds in L-isomers of tyrosine, phenylalanine, and tryptophan. In the active site of this enzyme, three amino acid residues work together to form a catalytic triad which makes up the catalytic site. In chymotrypsin, these residues are Ser-195, His-57 and Asp-102. The mechanism of chymotrypsin can be divided into two phases. First, Ser-195 nucleophilically attacks the peptide bond carbon in the substrate to form a tetrahedral intermediate. The nucleophilicity of Ser-195 is enhanced by His-57, which abstracts a proton from Ser-195 and is in turn stabilised by the negatively charged carboxylate group (RCOO−) in Asp-102. Furthermore, the tetrahedral oxyanion intermediate generated in this step is stabilised by hydrogen bonds from Ser-195 and Gly-193. In the second stage, the R'NH group is protonated by His-57 to form R'NH2 and leaves the intermediate, leaving behind the acylated Ser-195. His-57 then acts as a base again to abstract one proton from a water molecule. The resulting hydroxide anion nucleophilically attacks the acyl-enzyme complex to form a second tetrahedral oxyanion intermediate, which is once again stabilised by H bonds. In the end, Ser-195 leaves the tetrahedral intermediate, breaking the CO bond that connected the enzyme to the peptide substrate. A proton is transferred to Ser-195 through His-57, so that all three amino acid return to their initial state.
Bicalutamide has an antiandrogenic efficacy that is comparable to or greater than that of flutamide, and would be expected to produce similar therapeutic benefits. Other androgen-dependent skin and hair conditions, such as seborrhea and pattern hair loss, may also be treated by bicalutamide. In addition to acne, flutamide has been found to produce an 80% or greater decrease in scores of seborrhea and androgen-dependent scalp hair loss. Moreover, in combination with a combined birth control pill, flutamide treatment resulted in an increase in cosmetically acceptable scalp hair density in almost all women suffering from pattern hair loss in one small study. Bicalutamide is an appealing alternative to flutamide for the treatment of androgen-dependent skin and hair conditions in women because flutamide has a considerable risk of serious liver toxicity, which bicalutamide does not share. Antiandrogens like flutamide and bicalutamide are male-specific teratogens which can feminize male fetuses due to their antiandrogen effects. For this reason, they are not recommended by the U.S.Tooltip United States Food and Drug Administration for use in women. Because of this risk, it is strongly recommended that antiandrogens only be used to treat women who are of reproductive age in conjunction with adequate contraception. Birth control pills, which contain an estrogen and a progestin, are typically used for this purpose.
Historic England. "Bawdsey Chain Home Station (1309533)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Great Bromley Chain Home Station (1476819)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Canewdon Chain Home Station (1412472)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Dunkirk Chain Home Station (1377189)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "High Street Chain Home Station (1476863)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Pevensey Chain Home Station (1476551)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Rye Chain Home Station (1476520)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Ventnor Chain Home Station (1306901)". Research records (formerly PastScape). Retrieved 9 October 2015. Early Radar Memories Archived 2 September 2010 at the Wayback Machine Memories of Sgt. Jean Semple, one of Britain's pioneer radar operators RAF Bawdsey Chain Home Radar Station at Subterranean Britain RAF Radar Museum RAF High Street picture Life at Darsham Deprecated link archived 19 April 2013 at archive.today – BBC Great Baddow Chain Home Mast & Radar Anniversary Chain Home Radar – A Personal Reminiscence, M Scanlan, GEC Review, 1993 Early radar development in the UK at purbeckradar.co.uk 60 (Signals) Group, Fighter Command Archived 16 November 2017 at the Wayback Machine (pdf)
Sources: en.wikipedia.org
== Medical uses == Insulin icodec is used as a basal insulin to improve glycemic control in adults with diabetes. Indications vary by jurisdiction. In the United States, insulin icodec is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In the European Union, insulin icodec is authorized for adults with diabetes. In people with type 1 diabetes, it is indicated together with short-acting insulin to cover mealtime insulin requirements. In people with type 2 diabetes, it may be used alone or with other diabetes medicines, including short-acting insulin.
=== Synaptogenesis === BDNF also enhances synaptogenesis. Synaptogenesis is dependent upon the assembly of new synapses and the disassembly of old synapses by β-adducin. Adducins are membrane-skeletal proteins that cap the growing ends of actin filaments and promote their association with spectrin, another cytoskeletal protein, to create stable and integrated cytoskeletal networks. Actins have a variety of roles in synaptic functioning. In pre-synaptic neurons, actins are involved in synaptic vesicle recruitment and vesicle recovery following neurotransmitter release. In post-synaptic neurons they can influence dendritic spine formation and retraction as well as AMPA receptor insertion and removal. At their C-terminus, adducins possess a myristoylated alanine-rich C kinase substrate (MARCKS) domain which regulates their capping activity. BDNF can reduce capping activities by upregulating PKC, which can bind to the adducing MRCKS domain, inhibit capping activity, and promote synaptogenesis through dendritic spine growth and disassembly and other activities.
===== Inter-American Commission on Human Rights ===== A case was filed with the IACHR on behalf of the wife of a Colombian man allegedly killed in the 15 September strike by Colombian president Petro's personal lawyer, Dan Kovalik, accusing "the United States of violating the rights to life, equality before the law, recognition of legal personality, a fair trial, and due process", according to El País. In an 8 December interview with Democracy Now!, prosecutor Reed Brody called the strikes murder, distinguishing them from war crimes because they took place in the absence of a legitimate conflict. He compared the actions of the US to the actions for which Rodrigo Duterte is on trial at the International Criminal Court, saying both countries had endorsed the killing of suspected drug traffickers without trial.
== History == In 1891 G. Merling obtained a water-soluble bromine-containing compound from the reaction of cycloheptatriene and bromine. Unlike most alkyl bromides, this compound, later named tropylium bromide, is water-soluble but insoluble in many organic solvents. It is purified by crystallization from hot ethanol. Reaction with aqueous silver nitrate immediately gave silver bromide, indicating labile bromide. Tropylium bromide was deduced to be a salt, C7H+7Br−, by Doering and Knox in 1954 by analysis of its infrared and ultraviolet spectra. The ionic structures of tropylium perchlorate (C7H+7ClO−4) and tropylium iodide (C7H+7I−) have been confirmed by X-ray crystallography. The bond length of the carbon-carbon bonds is longer (147 pm) than those of benzene (140 pm) but still shorter than those of a typical single-bonded species like ethane (154 pm).
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate), and for major depressive disorder as an adjunctive therapy only (with an oral antidepressant). It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. Lumateperone was approved for medical use in the US in December 2019 with an initial indication for schizophrenia. It became available in February 2020.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.